Citius Oncology (CTOR) vs Evolus (EOLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Evolus (EOLS) has outperformed Citius Oncology (CTOR) over the past year, gaining 25.6% versus a loss of 54.6%. Evolus is the larger company by market cap ($515.2 million vs $88.3 million), about 5.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTOR | EOLS |
|---|---|---|
| Share price | $0.835 | $7.80 |
| Market cap | $88.31M | $515.19M |
| 1-day change | -2.45% | +0.78% |
| YTD return | -16.50% | +17.29% |
| 1-year return | -54.62% | +25.60% |
| 5-year return | — | +1.69% |
| Forward P/E | — | 26.67 |
| EPS (TTM) | $-0.48 | $-0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.25 | $9.31 |
| 52-week low | $0.491 | $3.86 |
| Distance from 52-week high | -62.89% | -16.22% |
| Analyst consensus | none | none |
| Avg. price target upside | +379.04% | +92.31% |
| Average volume | 99.72K | 900.79K |
| Shares outstanding | 105.76M | 66.05M |
| Employees | — | 353 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Evolus is about 5.8 times larger than Citius Oncology by market value ($515.19M vs $88.31M).
- EOLS has outperformed CTOR by 80.2 percentage points over the past year.
About Citius Oncology
CTOR stock →Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies.
Healthcare · Drug Manufacturers - Specialty & Generic
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Healthcare · Drug Manufacturers - Specialty & Generic · 353 employees
CTOR vs EOLS FAQ
Which is bigger, Citius Oncology or Evolus?
Evolus (EOLS) is larger, with a market capitalization of $515.19M compared with $88.31M for Citius Oncology (CTOR).
Which stock has performed better over the past year, CTOR or EOLS?
EOLS returned +25.60% over the past 12 months, compared with -54.62% for CTOR (price return, excluding dividends). Past performance does not predict future results.
Are Citius Oncology and Evolus in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.